Surrozen (SRZN) Free Cash Flow Growth (1y) (2021 - 2026)
Surrozen (SRZN) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Surrozen |
235,841.47 |
-106.67 Mn |
- |
-35.25% |
| Date | Value |
|---|
| Mar 31, 2026 |
-35.25% |
| Dec 31, 2025 |
-272.65% |
| Sep 30, 2025 |
-33.65% |
| Jun 30, 2025 |
-8.15% |
| Mar 31, 2025 |
-7.12% |
| Dec 31, 2024 |
148.04% |
| Sep 30, 2024 |
33.68% |
| Jun 30, 2024 |
35.95% |
| Mar 31, 2024 |
39.89% |
| Dec 31, 2023 |
-2,279.10% |
| Sep 30, 2023 |
28.79% |
| Jun 30, 2023 |
25.29% |
| Mar 31, 2023 |
21.28% |
| Dec 31, 2022 |
102.83% |
| Sep 30, 2022 |
3.70% |
| Jun 30, 2022 |
9.05% |
| Mar 31, 2022 |
-77.45% |
| Dec 31, 2021 |
-750.37% |
| Sep 30, 2021 |
-49,390.00% |
